WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H598132
CAS#: 85466-18-8
Description: Thymocartin is the 32-35 fragment of the naturally occurring thymic factor (thymopoietin).
Hodoodo Cat#: H598132
Name: Thymocartin
CAS#: 85466-18-8
Chemical Formula: C21H40N8O7
Exact Mass: 516.30
Molecular Weight: 516.600
Elemental Analysis: C, 48.83; H, 7.80; N, 21.69; O, 21.68
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Thymocartin; RGH 0206; Thymocartinum;
IUPAC/Chemical Name: (6S,9S,12S,15S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-1-imino-15-isopropyl-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oic acid
InChi Key: COIXXKVZEXZCLU-YXWQFLTLSA-N
InChi Code: InChI=1S/C21H40N8O7/c1-11(2)16(20(35)36)29-19(34)14(10-15(30)31)28-18(33)13(7-3-4-8-22)27-17(32)12(23)6-5-9-26-21(24)25/h11-14,16H,3-10,22-23H2,1-2H3,(H,27,32)(H,28,33)(H,29,34)(H,30,31)(H,35,36)(H4,24,25,26)/t12-,13-,14-,16-/m0/s1
SMILES Code: CC(C)[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)N)=O)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 516.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Schmidt MC, Rubas W, Merkle HP. Nasal epithelial permeation of thymotrinan (TP3) versus thymocartin (TP4): competitive metabolism and self-enhancement. Pharm Res. 2000 Feb;17(2):222-8. PubMed PMID: 10751039.
2: Lang S, Langguth P, Oschmann R, Traving B, Merkle HP. Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. J Pharm Pharmacol. 1996 Nov;48(11):1190-6. PubMed PMID: 8961171.
3: Narayana JL, Huang HN, Wu CJ, Chen JY. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget. 2015 May 30;6(15):12936-54. PubMed PMID: 26002554; PubMed Central PMCID: PMC4536990.
4: Felder ChB, Blanco-Príeto MJ, Heizmann J, Merkle HP, Gander B. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters. J Microencapsul. 2003 Sep-Oct;20(5):553-67. PubMed PMID: 12909541.
5: Gazdag M, Mihályfi K, Kemenesné BP, Görög S. [High performance liquid chromatography and capillary electrophoresis investigation of the neww immunostimulant tetrapeptide drug, thymocartin]. Acta Pharm Hung. 1997 Sep;67(5):169-74. Hungarian. PubMed PMID: 9432863.
6: Zhang Y, Feng J, Cui L, Zhang Y, Li W, Li C, Shi N, Chen Y, Kong W. Investigation Into Efficiency of a Novel Glycol Chitosan-Bestatin Conjugate to Protect Thymopoietin Oligopeptides From Enzymatic Degradation. J Pharm Sci. 2016 Feb;105(2):828-837. doi: 10.1002/jps.24567. Epub 2016 Jan 11. PubMed PMID: 26173563.
7: Reithmeier H, Herrmann J, Göpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001 Jun 15;73(2-3):339-50. PubMed PMID: 11516510.
8: Lapis K, Timár J, Pápay J, Paku S, Szende B, Ladányi A. Experimental metastasis inhibition by pretreatment of the host. Arch Geschwulstforsch. 1990;60(2):97-102. PubMed PMID: 2111128.
9: Dénes L, Hajós G, Szporny L, Szende B, Lapis K, Sipka S, Szegedi G. The effect of thymopoietin 32-34 (TP3) on suramin-induced inhibition on delayed type hypersensitivity in guinea pigs. Immunol Invest. 1987 Jun;16(4):275-9. PubMed PMID: 3323037.
10: Szende B, Kisfaludy L, Lapis K, Dénes L, Szporny L, Nyéke O, Schön I, Hajós G, Ember J, Constantin M, et al. The effect of TP-5 and its analogs on skin grafts in mice. J Immunopharmacol. 1985;7(1):67-78. PubMed PMID: 3891868.
11: Szendrei GI, Fabian H, Mantsch HH, Lovas S, Nyéki O, Schön I, Otvos L Jr. Aspartate-bond isomerization affects the major conformations of synthetic peptides. Eur J Biochem. 1994 Dec 15;226(3):917-24. Erratum in: Eur J Biochem 1995 Aug 1;231(3):868. PubMed PMID: 7813483.
12: Dénes L, Szende B, Hajós G, Szporny L, Lapis K. Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models. Drugs Exp Clin Res. 1987;13(5):279-87. PubMed PMID: 3500029.
13: Heizmann J, Langguth P, Biber A, Oschmann R, Merkle HP, Wolffram S. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides. 1996;17(7):1083-9. PubMed PMID: 8959740.
14: Iván E, Bodrogligeti I, Juhász-Nagy A, Német L, Cholnoky E. Preclinical toxicity studies with two thymopoietin-like peptides. Arch Toxicol Suppl. 1985;8:495-8. PubMed PMID: 3868381.
15: Nagy J, Kapás M. In vitro degradation of thymopoietin32-35 in human, dog and rat plasma. Acta Physiol Hung. 1995;83(1):31-7. PubMed PMID: 7660834.
16: Anderlik P, Szeri I, Bános Z, Barna Z. The course of LCMV infection in euthymic and athymic mice pretreated with immunomodulatory agents. Acta Microbiol Hung. 1992;39(3-4):235-9. PubMed PMID: 1343936.
17: Rajnavölgyi E, Kulics J, Szilágyvári M, Kisfaludy L, Nyéki O, Schön I, Gergely J. The influence of new thymopoietin derivatives on the immune response of inbred mice. Int J Immunopharmacol. 1986;8(2):167-77. PubMed PMID: 3519478.
18: Anderlik P, Bános Z, Szeri I, Barna Z. [Effect of pretreatment with immunomodulating agents on the outcome of lymphocytic choriomeningitis virus infection in athymic (nude) and euthymic mice]. Acta Pharm Hung. 1992 Jul;62(4):167-71. Hungarian. PubMed PMID: 1442095.
19: Anderlik P, Antmann K, Cseh K, Kalabay L. [Role of the thymus and normal microbial flora on plasma fibronectin concentration in mice treated with immunomodulatory drugs]. Acta Pharm Hung. 1996 Jul;66(4):165-9. Hungarian. PubMed PMID: 9082837.